The Washington University Alzheimer's Disease Research Center (ADRC) initiates, fosters, and supports the performance of innovative, cutting-edge research on Alzheimer's disease (AD) and related topics with regard to the etiology, pathogenesis, diagnosis, treatment, and prevention of disease. We provide well-characterized research participants (persons with AD and age-matched controls), their clinical, psychometric, and imaging data, and their tissue (blood, DNA, CSF, autopsy material) to research projects. We also provide intellectual and financial support to scientists at Washington University, at other Alzheimer's Centers, and the research community nationally and internationally and engage in formal and informal collaborations, including multi-disciplinary/multi-Center studies and the initiatives sponsored by the National Institute on Aging, the National Alzheimer Coordinating Center, and the National Cell Repository for Alzheimer's Disease. Historically, our Center has focused on the earliest stages of dementia to identify the initial clinical and pathologic changes that distinguish AD from normal aging. Our approach is balanced between clinicopathologic and basic science domains with emphasis on interdisciplinary efforts. We will continue our training of students, fellows and junior faculty in clinical and basic science research skills. We will continue to engage in outreach activities to transfer information on AD to lay and professional audiences. We have a commitment to underserved populations that are the focus of our African American and Rural Satellites and will continue activities that promote the inclusion of these populations in research. This competing renewal application includes six cores: A: Administration, B: Clinical, C: Data Management and Statistics, D: Neuropathology, E: Education and F: Genetics. There are two satellites: African American (Core B: Clinical) and Rural (Core E: Education). The ADRC resources contained in these Cores and Satellites will promote and advance AD-related research as represented by the three projects in this application: Project 1. Novel protein biomarkers for Alzheimer's disease in cerebrospinal fluid;(Richard Perrin) 2. Changing tau protein levels and tau protein isoforms in mouse models of dementia;(Timothy Miller) 3. APOE metabolism in AD and controls;(Randall Bateman).

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
2P50AG005681-27
Application #
7837523
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (J2))
Program Officer
Phelps, Creighton H
Project Start
1997-06-15
Project End
2015-04-30
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
27
Fiscal Year
2010
Total Cost
$2,570,270
Indirect Cost
Name
Washington University
Department
Neurology
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Moga, Daniela C; Abner, Erin L; Wu, Qishan et al. (2017) Bladder antimuscarinics and cognitive decline in elderly patients. Alzheimers Dement (N Y) 3:139-148
Wildburger, Norelle C; Esparza, Thomas J; LeDuc, Richard D et al. (2017) Diversity of Amyloid-beta Proteoforms in the Alzheimer's Disease Brain. Sci Rep 7:9520
Sennik, Simrin; Schweizer, Tom A; Fischer, Corinne E et al. (2017) Risk Factors and Pathological Substrates Associated with Agitation/Aggression in Alzheimer's Disease: A Preliminary Study using NACC Data. J Alzheimers Dis 55:1519-1528
Roe, Catherine M; Babulal, Ganesh M; Head, Denise M et al. (2017) Preclinical Alzheimer's disease and longitudinal driving decline. Alzheimers Dement (N Y) 3:74-82
Neu, Scott C; Pa, Judy; Kukull, Walter et al. (2017) Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis. JAMA Neurol 74:1178-1189
Miller-Thomas, Michelle M; Benzinger, Tammie L S (2017) Neurologic Applications of PET/MR Imaging. Magn Reson Imaging Clin N Am 25:297-313
Alosco, Michael L; Duskin, Jonathan; Besser, Lilah M et al. (2017) Modeling the Relationships Among Late-Life Body Mass Index, Cerebrovascular Disease, and Alzheimer's Disease Neuropathology in an Autopsy Sample of 1,421 Subjects from the National Alzheimer's Coordinating Center Data Set. J Alzheimers Dis 57:953-968
Roe, Catherine M; Barco, Peggy P; Head, Denise M et al. (2017) Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals. Alzheimer Dis Assoc Disord 31:69-72
Pandya, Seema Y; Lacritz, Laura H; Weiner, Myron F et al. (2017) Predictors of Reversion from Mild Cognitive Impairment to Normal Cognition. Dement Geriatr Cogn Disord 43:204-214
Lewczuk, Piotr; Matzen, Anja; Blennow, Kaj et al. (2017) Cerebrospinal Fluid A?42/40 Corresponds Better than A?42 to Amyloid PET in Alzheimer's Disease. J Alzheimers Dis 55:813-822

Showing the most recent 10 out of 825 publications